iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Update

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totaling 27,456 shares, a decline of 42.2% from the April 30th total of 47,511 shares. Approximately 0.5% of the shares of the company are short sold. Based on an average trading volume of 57,909 shares, the days-to-cover ratio is presently 0.5 days.

iShares Genomics Immunology and Healthcare ETF Price Performance

IDNA traded down $0.64 during trading on Tuesday, hitting $28.68. The stock had a trading volume of 69,543 shares, compared to its average volume of 40,833. The company has a 50 day moving average price of $29.53 and a 200-day moving average price of $28.58. The firm has a market cap of $156.31 million, a price-to-earnings ratio of 14.76 and a beta of 0.97. iShares Genomics Immunology and Healthcare ETF has a one year low of $20.15 and a one year high of $31.41.

Institutional Trading of iShares Genomics Immunology and Healthcare ETF

A number of institutional investors have recently modified their holdings of the stock. Portland Global Advisors LLC lifted its position in shares of iShares Genomics Immunology and Healthcare ETF by 0.7% during the 3rd quarter. Portland Global Advisors LLC now owns 103,007 shares of the company’s stock worth $2,432,000 after buying an additional 684 shares during the last quarter. Ameriprise Financial Inc. lifted its position in shares of iShares Genomics Immunology and Healthcare ETF by 8.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 71,473 shares of the company’s stock worth $1,688,000 after buying an additional 5,540 shares during the last quarter. Finally, Triumph Capital Management bought a new stake in shares of iShares Genomics Immunology and Healthcare ETF during the 3rd quarter worth $35,000.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.